Another deal, cholesterol drug developer Aegerion Pharmaceuticals Inc., priced shares of its IPO far below expectations Friday after twice delaying the offering. It closed up nearly 14 percent, however.
Investors Seek Out Chinese, Consumer IPOs
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts